Abstract: Langerhans cell histiocytosis is rare and more frequent in children. The skin is affected in 50% of the cases and is the only site in 10%. Its course varies from self-limited and localized forms to severe multisystemic forms. Congenital cases are usually exclusively cutaneous and self-limited, with spontaneous remission in months. This study presents a rare congenital case, initially restricted to the skin, with subsequent dissemination and fatal outcome. A male newborn presented congenital disseminated erythematous scaly lesions. The biopsy was conclusive for Langerhans cell histiocytosis. The patient evolved into the multisystemic form in weeks, when chemotherapy was started, according to the LCH-2009 protocol; however, the patient was refractory to treatment and died.
INTRODUCTION
Langerhans cell histiocytosis (LCH) is rare and results from clonal proliferation of cells, which are similar to Langerhans cells (LC). Its incidence is three to five cases per million. It may appear at any age, but it is most frequent in children. 1, 2 In the neonatal period, incidence is one to two cases per million. 3 The most affected organs are bones and lymph nodes. The skin is affected in 50% of the cases and is the only site in 10%. Its course varies from self-limited and localized forms to severe multisystemic forms. The study presents congenital case initially restricted to the skin, with dissemination and fatal outcome. In the fifth week of treatment, the patient developed suppurative otorrhea in the right ear without general symptoms. It was difficult to establish whether there was progression of disease with extension to another organ (bone), whether the clinical picture was secondary to otitis externa due to the disease itself or whether the picture was of infectious nature. The infant was hospitalized and treated with cefepima, producing a good response and complete resolution of the lesion after seven days of treatment. The final diagnosis was necrotizing otitis externa.
CASE REPORT
In the sixth week the patient was classified as "stable disease with involvement of target organ", and the protocol was followed as planned, with intravenous chemotherapy for six more weeks.
In the 12th week reassessment, there were signs of progression of the disease, with a worsening of the skin lesions and hema- or multifocal chronic disease, focal or eosinophilic granuloma, and
Hashimoto Pritzker disease. 5 The congenital cases described in these studies are mostly forms that are exclusively cutaneous and self-limited, with spontaneous remission occurring in months. There are rare cases reported of the progression of the diseases, together with the compromising of other organs. Even more rare are studies with fatal outcomes. 6 Extensive skin lesions do not indicate severity, and all patients must be followed up even after spontaneous remission. 3 There are no reliable clinical and laboratory predictors that identify patients at risk of developing the multisystem form. Promising results were also obtained with the use of cytarabine. 9 Currently, LCH is understood as a spectral disease with a wide variation of clinical presentations and unpredictable clinical course. LCH is rarely congenital. This study presents a case of congenital LCH with only skin lesions initially, followed by dissemination to other organs, refractory reaction to treatment, and a fatal outcome. It is important to recognize the need to monitor patients over the long term, regardless of the clinical form of presentation concerning the risk of dissemination, as well as to achieve an early histological diagnosis.q
